Skip to main content

Advertisement

Log in

Outcome measures in systemic sclerosis: An update on instruments and current research

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Substantial progress has been made in the past 10 years in the development and validation of outcome measures and refinement of trial methodology for systemic sclerosis (scleroderma, SSc). These advances in outcome measures have focused mostly on specific organ systems involved in SSc. Many of these new tools have been validated and subsequently adapted for use in multicenter clinical trials. Newer outcome measures in development are intended to more precisely quantify clinically meaningful change in specific organ systems, and some methods aim to assess overall disease burden in SSc. This review provides an update on currently used outcome measures in SSc with specific attention on newer tools and also describes methodology under development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Altman RD, Medsger TA Jr, Bloch DA, Michel BA: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991, 34:403–413.

    Article  PubMed  CAS  Google Scholar 

  2. Merkel PA, Clements PJ, Reveille JD, et al.: Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003, 30:1630–1647.

    PubMed  Google Scholar 

  3. White B, Bauer EA, Goldsmith LA, et al.: Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995, 38:351–360.

    Article  PubMed  CAS  Google Scholar 

  4. Baroni SS, Santillo M, Bevilacqua F, et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667–2676.

    Article  PubMed  CAS  Google Scholar 

  5. Furst DE, Khanna D, Mattucci-Cerinic M, et al.: Scleroderma—developing measures of response. J Rheumatol 2005, 32:2477–2480.

    PubMed  Google Scholar 

  6. Boers M, Brooks P, Strand CV, Tugwell P: The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998, 25:198–199.

    PubMed  CAS  Google Scholar 

  7. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581–590.

  8. Clements PJ, Furst DE, Wong WK, et al.: High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999, 42:1194–1203.

    Article  PubMed  CAS  Google Scholar 

  9. Pope JE, Bellamy N, Seibold JR, et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001, 44:1351–1358.

    Article  PubMed  CAS  Google Scholar 

  10. Seibold JR, Korn JH, Simms R, et al.: Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000, 132:871–879.

    PubMed  CAS  Google Scholar 

  11. Mayes MD, O’Donnell D, Rothfield NF, Csuka ME: Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 2004, 50:553–557.

    Article  PubMed  CAS  Google Scholar 

  12. Clements P, Lachenbruch P, Siebold J, et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281–1285.

    PubMed  CAS  Google Scholar 

  13. Clements PJ, Hurwitz EL, Wong WK, et al.: Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000, 43:2445–2454.

    Article  PubMed  CAS  Google Scholar 

  14. Kissin EY, Schiller AM, Gelbard RB, et al.: Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006, 55:603–609.

    Article  PubMed  Google Scholar 

  15. Merkel PA, Silliman N, Denton CP, et al.: Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial [abstract]. Arthritis Rheum 2004, 50:S419.

    Google Scholar 

  16. Moore TL, Lunt M, McManus B, et al.: Seventeen-point dermal ultrasound scoring system—a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology (Oxford) 2003, 42:1559–1563.

    Article  CAS  Google Scholar 

  17. Akesson A, Hesselstrand R, Scheja A, Wildt M: Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis. Ann Rheum Dis 2004, 63:791–796.

    Article  PubMed  CAS  Google Scholar 

  18. Steen VD, Conte C, Owens GR, Medsger TA Jr: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  19. Tashkin DP, Elashoff R, Clements PJ, et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655–2666.

    Article  PubMed  CAS  Google Scholar 

  20. Rubin LJ, Badesch DB, Barst RJ, et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896–903.

    Article  PubMed  CAS  Google Scholar 

  21. Simonneau G, Barst RJ, Galie N, et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800–804.

    PubMed  Google Scholar 

  22. Badesch DB, Tapson VF, McGoon MD, et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425–434.

    PubMed  CAS  Google Scholar 

  23. Desai SR, Veeraraghavan S, Hansell DM, et al.: CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004, 232:560–567.

    Article  PubMed  Google Scholar 

  24. Kazerooni EA, Martinez FJ, Flint A, et al.: Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997, 169:977–983.

    PubMed  CAS  Google Scholar 

  25. Schettino IA, Ab’saber AM, Vollmer R, et al.: Accuracy of high resolution CT in assessing idiopathic pulmonary fibrosis histology by objective morphometric index. Pathol Res Pract 2002, 198:347–354.

    Article  PubMed  Google Scholar 

  26. Clements PJ, Goldin JG, Kleerup EC, et al.: Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004, 50:1909–1917.

    Article  PubMed  Google Scholar 

  27. Miyamoto S, Nagaya N, Satoh T, et al.: Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000, 161(2 Pt 1):487–492.

    PubMed  CAS  Google Scholar 

  28. Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296–302.

    Article  PubMed  CAS  Google Scholar 

  29. Buch MH, Denton CP, Furst DE, et al.: Sub-maximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: Reproducibility and correlations of the six minute walk test. Ann Rheum Dis 2006, Epub ahead of print.

  30. Lederer DJ, Arcasoy SM, Wilt JS, et al.: Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:659–664.

    Article  PubMed  Google Scholar 

  31. Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751–758.

    PubMed  CAS  Google Scholar 

  32. Khanna D, Clements PJ, Furst DE, et al.: Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005, 52:592–600.

    Article  PubMed  Google Scholar 

  33. Martinez TY, Pereira CA, dos Santos ML, et al.: Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000, 117:1627–1632.

    Article  PubMed  CAS  Google Scholar 

  34. Steen VD, Medsger TA Jr: The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997, 40:1984–1991.

    Article  PubMed  CAS  Google Scholar 

  35. Sjogren RW: Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996, 8:569–575.

    Article  PubMed  CAS  Google Scholar 

  36. Khanna D, Hays RD, Park GS, et al.: Development of the scleroderma gastrointestinal tract 1.0 (SSc-GIT 1.0) quality of life instrument—preliminary report. Arthritis Rheum 2007, in press.

  37. Horikoshi T, Matsuzaki T, Sekiguchi T: Effect of H2-receptor antagonists cimetidine and famotidine on interdigestive gastric motor activity and lower esophageal sphincter pressure in progressive systemic sclerosis. Intern Med 1994, 33:407–412.

    PubMed  CAS  Google Scholar 

  38. Wang SJ, La JL, Chen DY, et al.: Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 2002, 21:43–45.

    Article  PubMed  CAS  Google Scholar 

  39. Merkel PA, Herlyn K, Martin RW, et al.: Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002, 46:2410–2420.

    Article  PubMed  Google Scholar 

  40. Fries R, Shariat K, von Wilmowsky H, Bohm M: Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 2005, 112:2980–2985.

    PubMed  CAS  Google Scholar 

  41. Wigley FM, Wise RA, Seibold JR, et al.: Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994, 120:199–206.

    PubMed  CAS  Google Scholar 

  42. Dziadzio M, Denton CP, Smith R, et al.: Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999, 42:2646–2655.

    Article  PubMed  CAS  Google Scholar 

  43. Korn JH, Mayes M, Matucci CM, et al.: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985–3993.

    Article  PubMed  CAS  Google Scholar 

  44. Khanna D, Furst DE, Clements PJ, et al.: Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005, 32:832–840.

    PubMed  Google Scholar 

  45. Cole JC, Khanna D, Clements PJ, et al.: Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006, 15:1383–1394.

    Article  PubMed  Google Scholar 

  46. Khanna D, Furst DE, Hays RD, et al.: Minimally important difference in diffuse systemic sclerosis—results from the D-penicillamine study. Ann Rheum Dis 2006, 65:1325–1329.

    Article  PubMed  CAS  Google Scholar 

  47. Weinstein MC, Siegel JE, Gold MR, et al.: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996, 276:1253–1258.

    Article  PubMed  CAS  Google Scholar 

  48. Khanna D, Hays RD, Furst DE, et al.: Assessment of SF-6D, a preference measure, in systemic sclerosis [abstract]. Arthritis Rheum 2006, 52:S346.

    Google Scholar 

  49. Silman A, Akesson A, Newman J, et al.: Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument. J Rheumatol 1998, 25:79–83.

    PubMed  CAS  Google Scholar 

  50. Khanna D, Ahmed M, Furst DE, et al.: Health values of patients with systemic sclerosis. Arthritis Rheum 2007, 57:86–93.

    Article  PubMed  Google Scholar 

  51. Kissin EY, Merkel PA, Lafyatis R: Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006, 54:3655–3660.

    Article  PubMed  Google Scholar 

  52. Williams MH, Handler CE, Akram R, et al.: Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006, 27:1485–1494.

    Article  PubMed  CAS  Google Scholar 

  53. Steen VD: Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35–42.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dinesh Khanna MD, MS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khanna, D., Merkel, P.A. Outcome measures in systemic sclerosis: An update on instruments and current research. Curr Rheumatol Rep 9, 151–157 (2007). https://doi.org/10.1007/s11926-007-0010-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0010-5

Keywords

Navigation